三叔丁基膦 | 13716-12-6

• 物质功能分类: 有机原料 - 有机膦化合物
• 分子结构分类: 有机化合物 - 有机磷化合物 - 有机膦及其衍生物
• 中文名称: 三叔丁基膦
• 中文别名: 三特丁基膦；TTBP；三叔丁基磷
• 英文名称: tri-tert-butyl phosphine
• 英文别名: Tris(tert-butyl)phosphine；P(t-Bu)3；t-Bu3P；tri-t-butylphosphine；tri-tert-butylphosphorus；TTBP；tri-tert-butylphosphane；ri-tert-butylphosphine；tri-tert-butylphosphin；Tri-tert-butylphosphine；tritert-butylphosphane
• CAS: 13716-12-6
• 化学式: C₁₂H₂₇P
• mdl: MFCD00015006
• 分子量: 202.32
• InChiKey: BWHDROKFUHTORW-UHFFFAOYSA-N

物化性质

• 熔点：
  30-35 °C(lit.)
• 沸点：
  102-103 °C13 mm Hg(lit.)
• 密度：
  0.861 g/mL at 25 °C
• 闪点：
  1 °F
• 稳定性/保质期：
  对空气非常敏感，必须在低温下隔绝空气保存。对其进行操作时，必须在手套箱或惰性气体保护下进行。

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

安全信息

• 危险等级：
  4.2
• 危险品标志：
  F,C
• 安全说明：
  S16,S25,S26,S27,S36/37/39,S43,S45,S62
• 危险类别码：
  R17,R34
• WGK Germany：
  3
• 海关编码：
  2931900090
• 危险品运输编号：
  UN 2846 4.2/PG 1
• 危险类别：
  4.2
• 包装等级：
  I
• 危险标志：
  GHS02,GHS05
• 危险性描述：
  H250,H314
• 危险性防范说明：
  P222,P231,P280,P305 + P351 + P338,P310,P422
• 储存条件：
  在低温下隔绝空气保存。

SDS

Name:	Tri-tert-butylphosphine 95% Material Safety Data Sheet
Synonym:
CAS:	13716-12-6

Section 1 - Chemical Product MSDS Name:Tri-tert-butylphosphine 95% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
13716-12-6	Tri-tert-butylphosphine	95%	237-266-4

Hazard Symbols: F C
Risk Phrases: 17 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Spontaneously flammable in air. Causes burns.Air sensitive.
Potential Health Effects
Eye:
Causes eye burns. Lachrymator (substance which increases the flow of tears).
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. If victim is conscious and alert, give 2-4 cupfuls of milk or water. Get medical aid immediately.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. Material can spontaneously ignite (pyrophoric) when exposed to air at normal or slightly elevated temperatures.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Remove all sources of ignition.
Use a spark-proof tool.

---

Section 7 - HANDLING and STORAGE
Handling:
Use spark-proof tools and explosion proof equipment. Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood. Store and handle protected from air.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Flammables-area. Do not expose to air. Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 13716-12-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: colorless
Odor: unpleasant odor
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 102 - 103 deg C @ 13.00mm Hg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: -17 deg C ( 1.40 deg F)
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water: Insoluble.
Specific Gravity/Density: .8200g/cm3
Molecular Formula: C12H27P
Molecular Weight: 202.32

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, ignition sources, exposure to air.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of phosphorus, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 13716-12-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Tri-tert-butylphosphine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: PYROPHORIC LIQUID, ORGANIC, N.O.S.*
Hazard Class: 4.2
UN Number: 2845
Packing Group: I
IMO
Shipping Name: PYROPHORIC LIQUID, ORGANIC, N.O.S.
Hazard Class: 4.2
UN Number: 2845
Packing Group: I
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: F C
Risk Phrases:
R 17 Spontaneously flammable in air.
R 34 Causes burns.
Safety Phrases:
S 25 Avoid contact with eyes.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 13716-12-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 13716-12-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 13716-12-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

有机磷化合物：三叔丁基膦

三叔丁基膦（C₄H₉)₃P），是一种有机磷化合物，具有丁基基团和膦原子。它作为一种重要的有机合成中间体，在有机合成、催化剂及配位化学领域有着广泛的应用。

应用

作为新兴的第三代膦配体，三叔丁基膦近年来在钯催化偶联反应中表现出优异性能。由于其富电子特性以及较大的空间位阻，三叔丁基膦能够加速氧化加成反应并有利于原消除反应，从而显著加快偶联反应进程。

制备

在氩气保护下，向干燥的反应器中加入四氢呋喃作为溶剂，然后依次添加磷化钙、溴代叔丁烷以及镍催化剂。将混合物加热至60-80 ºC进行反应，随后用冷水淬灭反应。通过萃取、干燥和减压蒸馏步骤最终获得三叔丁基膦。

化学性质

三叔丁基膦（P(tBu)₃）是一种无色液体，在国内试剂公司有销售。商品化试剂通常为10%的正己烷和1,4-二氧杂环己烷溶液。对空气极其敏感，需在低温下隔绝空气保存，并且必须在手套箱中或惰性气体保护下操作。该化合物可以通过叔丁基氯化镁与三氯化磷在乙醚中的反应，然后用叔丁基锂处理来制备。

用途

在钯催化的偶联反应中，芳基硼酸与羟基醌的苯基碘叶立德反应时，三叔丁基膦是首选配体。此外，它还可以与Pd(dba)一起用于三甲基甲硅烷基烯醇醚与芳基卤化物的α-芳基化反应中。

反应信息

• 作为反应物：
  描述：

  三叔丁基膦 在 二叔丁基过氧化物 、 苯硫酚 作用下， 生成 乙基,1,1-二甲基-(9CI)
  参考文献：
  名称：

  伯、仲和叔烷基从苯硫酚中提取氢的绝对速率表达式

  摘要：

  用动力学吸收光谱 (KAS) 确定叔丁基、异丙基、正丁基和正辛基自由基从壬烷中的苯硫酚中提取氢的绝对速率表达式。烷基自由基是通过二烷基二硫化物的光解或二叔丁基过氧化物和三烷基膦在苯硫酚存在下的光解产生的。从 225 到 355 K，膦法中烷基的铼表达式如下：正丁基，log (k/M{sup {minus}1} s{sup {minus}1}) = (9.40 {plus minus} 0.13) - (1.74 {加减} 0.21)/{theta}, {theta} = 2.303RT kcal/mol; 异丙基，log (k/M{sup {minus}1} s{sup {minus}1}) = (9.26 {plus minus} 0.19) - (1.70 {plus minus} 0.21)/{theta}；叔丁基，log (k/M{sup {minus}1} s{sup {minus}1})

  DOI：

  10.1021/ja00183a040
• 作为产物：
  描述：

  溴代叔丁烷 在 calcium phosphide 、 nickel(II) acetylacetonate 作用下， 以 四氢呋喃 为溶剂， 反应 10.0h， 以95%的产率得到三叔丁基膦
  参考文献：
  名称：

  一种合成三叔丁基膦的方法

  摘要：

  本发明公开了一种合成三叔丁基膦的方法，属于有机合成领域。在无水无氧氛围中，以溴代叔丁烷为原料，在镍催化剂的催化作用下，与磷化钙反应生成三叔丁基膦。与现有技术相比本发明反应条件温和，操作简单，产率高，原料简单易得，降低了生产成本，适合工业化生产。

  公开号：

  CN109553639B
• 作为试剂：
  描述：

  4-联苯硼酸 、 1,4-dichloro-2,5-diphenylbenzene 在 tris-(dibenzylideneacetone)dipalladium(0) 、 四(三苯基膦)钯 、 三叔丁基膦 、 potassium carbonate 、 sodium t-butanolate 作用下， 以 乙醇 、 水 、 甲苯 为溶剂， 反应 48.0h， 生成
  参考文献：
  名称：

  一种双主体有机电致发光材料及有机电致发光器件

  摘要：

  本发明公开了一种双主体有机电致发光材料及有机电致发光器件，属于有机电致发光器件的技术领域。所述双主体有机电致发光材料包括第一主体化合物和第二主体化合物，所述第一主体化合物具有式1所示结构，所述第二主体化合物具有式2‑1或式2‑2所示结构。所述双主体有机电致发光材料可以使得三线态激子分散在两个主体化合物上，减少三重态‑三重态湮灭(TTA)造成的能量损失，进而使得有机电致发光材料具有较高的发光效率，将其用于有机电致发光器件的制备，可获得驱动电压低、发光效率高且使用寿命长的有机电致发光器件。

  公开号：

  CN117603124A

文献信息

• [EN] IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH<br/>[FR] DÉRIVÉS IMIDAZOLE UTILES COMME INHIBITEURS DE LA FAAH
  申请人：MERCK & CO INC

  公开号：WO2009152025A1

  公开（公告）日：2009-12-17

  The present invention is directed to certain imidazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.

  本发明涉及某些咪唑衍生物，其可用作脂肪酰胺水解酶（FAAH）的抑制剂。该发明还涉及包含这些化合物作为活性成分的药物配方，以及这些化合物及其配方在治疗某些疾病中的使用，包括骨关节炎、类风湿性关节炎、糖尿病性神经病、带状疱疹后神经痛、骨骼肌肉疼痛和纤维肌痛，以及急性疼痛、偏头痛、睡眠障碍、阿尔茨海默病和帕金森病。
• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• [EN] AURORA KINASE MODULATORS AND METHOD OF USE<br/>[FR] MODULATEURS D'AURORA KINASE ET PROCÉDÉ D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2009117157A1

  公开（公告）日：2009-09-24

  The present invention relates to chemical compounds having a general formula (I) wherein A1-5 and 7-8, D', L1, L2, R1, R3, R6-8, n and o are defined herein, and synthetic intermediates, which are capable of modulating the activity of Aurora kinase proteins and, thereby, influencing various disease states and conditions related to the activities of Aurora kinases. For example, the compounds are capable of influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

  本发明涉及具有一般式(I)的化合物，其中在此定义了A1-5和7-8，D'，L1，L2，R1，R3，R6-8，n和o，以及合成中间体，这些化合物能够调节枢纽激酶蛋白的活性，从而影响与枢纽激酶活动相关的各种疾病状态和病况。例如，这些化合物能够影响细胞周期和细胞增殖过程，以治疗癌症和与癌症相关的疾病。该发明还包括包括这些化合物的药物组合物，以及治疗与枢纽激酶活性相关的疾病状态的方法。
• Substituted imidazol-pyridazine derivatives
  申请人：——

  公开号：US20030229096A1

  公开（公告）日：2003-12-11

  The present invention relates to compounds of formula 1 wherein A is an unsubstituted or substituted cyclic group; and R is hydrogen or lower alkyl; or a pharmaceutically acceptable acid addition salt thereof. These compounds are NMDA NR-2B receptor subtype specific blockers and are useful in the treatment of neurodegeneration, depression and pain.

  本发明涉及以下式的化合物 1 其中A是未取代或取代的环状基团；以及 R是氢或较低的烷基； 或其药学上可接受的酸盐。这些化合物是NMDA NR-2B受体亚型特异性阻断剂，对于治疗神经退行性疾病、抑郁症和疼痛具有用处。
• [EN] MACROCYCLIC FACTOR VIIA INHIBITORS<br/>[FR] INHIBITEURS MACROCYCLIQUES DU FACTEUR VIIA
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2013184734A1

  公开（公告）日：2013-12-12

  The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are Factor VIIa inhibitors which may be used as medicaments.

  本发明提供了如规范中定义的Formula (I)的化合物，以及包含任何此类新化合物的组合物。这些化合物是Factor VIIa抑制剂，可用作药物。